Form 4: Organon Executive Kirke Weaver Reports Stock Transactions

General Counsel Kirke Weaver reported the vesting of restricted stock units and the withholding of shares for tax obligations.

Summary

• Kirke Weaver, General Counsel & Corp. Secy. of Organon & Co., executed transactions involving restricted stock units (RSUs) on March 31, 2026.
• A total of 18,513 shares were acquired through the vesting of RSUs.
• A total of 5,275 shares were withheld by the company to satisfy tax obligations at a price of $5.70 per share.
• The reporting person was granted a new award of 183,639 RSUs, which will vest in three equal annual installments starting March 31, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting routine executive compensation and tax compliance.

Positives

• The executive maintains a significant beneficial ownership stake of 92,639.163 shares following the transactions.
• The new RSU grant aligns the executive's long-term interests with shareholder value through a three-year vesting schedule.

Negatives

• The company withheld 5,275 shares to cover tax liabilities associated with the vesting of equity awards.

Risks

• The value of the equity holdings is subject to market volatility in Organon & Co. common stock.

Future Outlook

The newly granted 183,639 RSUs are scheduled to vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

Management Comments

• The transactions were conducted in accordance with the company's equity incentive plan.

Industry Context

StockSavvy.ai notes that this filing represents standard executive compensation activity within the pharmaceutical sector, where equity-based incentives are common for retaining key legal and corporate governance leadership.

Comparison to Industry Standards

• The use of RSU vesting and tax withholding is consistent with standard executive compensation practices at large-cap pharmaceutical companies like Merck, Pfizer, and Bristol Myers Squibb.

Stakeholder Impact

• Minimal impact on shareholders as these are standard equity compensation adjustments.

Next Steps

• Vesting of the first installment of the new RSU grant on March 31, 2027.

Key Dates

Keywords

Organon, OGN, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units